SUBSCRIBE TO TMCnet
TMCnet - World's Largest Communications and Technology Community

TMCNet:  Targeted Medical Pharma Selected as One of the

[January 27, 2014]

Targeted Medical Pharma Selected as One of the "Best Six Stocks" by Wall-Street.com

LOS ANGELES --(Business Wire)--

Targeted Medical Pharma, Inc. (OTCQB: TRGM) announced today that it has been selected as one of the best six stocks in the microcap space by industry specialist Wall-Street.com, a division of Wall-Street Media Co.

"We have worked very hard to be in a position to gain this type of recognition, and it is an honor to be chosen as one of the best six stocks by the industry specialist Wall-Street.com," said William Shell, M.D., CEO and Chief Scientific Officer of Targeted Medical Pharma, Inc. "Many of the companies Wall-Street.com ranks in their top 15 percent stand an excellent chance of delivering immense value to their shareholders, and we intend to achieve that goal by continuing to execute our business strategy."

About Wall-Street.com

Wall-Street.com was established in 1994 as one of the first financial websites dedicated to covering the growing microcap space. Wall-Street.com focuses on providing investors with detailed financial and industry information regarding microcap companies. Wall-Street.com was acquired by Wall-Street Media Co. in 2011.

About Targeted Medical Pharma, Inc.

Targeted Medical Pharma, Inc. is a Los Angeles-based biotechnology company that develops medical foods for the treatment of chronic disease, including pain syndromes, peripheral neuropathy, hypertension, obesity, sleep and cognitive disorders. The company also develops a line of dietary supplements designed to support health and wellness. The company manufactures 10 proprietary medical foods, 48 convenience kits and recently launched its first dietary supplement, Clearwayz™. The products are sold directly to physicians and pharmacies in the U.S. The company also is developing nutrient-based systems for oral stimulation of progenitor stem cells that differentiate into neurons, red blood cells, pituitary hormones including IGF-I.


Forward Looking Statement

This press release may contain forward-looking statements related to Targeted Medical Pharma's business strategy, outlook, objectives, plans, intentions or goals. The words "may," "will," "should," "plans," "explores," "expects," "anticipates," "continue," "estimate," "project," "intend," and similar expressions, identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Actual results could differ materially. Targeted Medical Pharma expressly disclaims any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company's expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based.

Twitter (News - Alert): https://twitter.com/tmedpharma
Google (News - Alert)+: https://plus.google.com/u/0/b/105401979573625142042/+Tmedpharma/posts
Facebook (News - Alert): https://www.facebook.com/TargetedMedicalPharma


[ Back To Technology News's Homepage ]

OTHER NEWS PROVIDERS







Technology Marketing Corporation

800 Connecticut Ave, 1st Floor East, Norwalk, CT 06854 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments: tmc@tmcnet.com.
Comments about this site: webmaster@tmcnet.com.

STAY CURRENT YOUR WAY

© 2014 Technology Marketing Corporation. All rights reserved | Privacy Policy